Selinexor as a Therapeutic Target: Advances in Non-small Cell and Small Cell Lung Cancer Treatment Strategies

Area of Science:

• Oncology
• Pharmacology

Background:

• Lung cancer remains a leading cause of cancer mortality worldwide.
• Current treatments for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) face challenges including drug resistance and limited efficacy.
• Novel therapeutic strategies are urgently needed to improve patient outcomes.

Purpose of the Study:

• To review the therapeutic potential of selinexor for lung cancer treatment.
• To explore the mechanisms of action of selinexor, a selective inhibitor of nuclear export (SINE).
• To summarize current evidence on selinexor's efficacy, particularly in preclinical models and combination therapies.

Main Methods:

• Literature review of preclinical studies and clinical trial data on selinexor in lung cancer.
• Analysis of selinexor's mechanism targeting nuclear export of tumor suppressor proteins.
• Evaluation of selinexor's efficacy in various lung cancer subtypes, including KRAS-mutant NSCLC and SCLC.

Main Results:

• Selinexor demonstrates significant preclinical efficacy against lung cancer models.
• Particular effectiveness was noted in KRAS-mutant NSCLC and in combination with chemotherapy for SCLC.
• The drug's mechanism involves inhibiting the nuclear export of key tumor suppressor proteins.

Conclusions:

• Selinexor represents a promising therapeutic agent for both NSCLC and SCLC.
• Combination therapies involving selinexor may overcome existing treatment limitations.
• Further clinical investigation is warranted to establish selinexor's role in lung cancer treatment strategies.